These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 3108909

  • 1. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives.
    Emrich HM, Berger M, Riemann D, von Zerssen D.
    Pharmacopsychiatry; 1987 Mar; 20(2):60-3. PubMed ID: 3108909
    [Abstract] [Full Text] [Related]

  • 2. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression--results of a double-blind study.
    Kasper S, Voll G, Vieira A, Kick H.
    Pharmacopsychiatry; 1990 May; 23(3):135-42. PubMed ID: 2115680
    [Abstract] [Full Text] [Related]

  • 3. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression.
    de Jonghe F, Swinkels J, Tuynman-Qua H.
    Pharmacopsychiatry; 1991 Jan; 24(1):21-7. PubMed ID: 1901418
    [Abstract] [Full Text] [Related]

  • 4. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine.
    Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J.
    Acta Psychiatr Scand; 1988 Dec; 78(6):668-75. PubMed ID: 3146890
    [Abstract] [Full Text] [Related]

  • 5. Oxaprotiline in the treatment of endogenous depressed inpatients an early clinical trial.
    Schmauss M, Laakmann G, Dieterle D, Blaschke D.
    Pharmacopsychiatry; 1985 Jul; 18(4):282-5. PubMed ID: 3895255
    [Abstract] [Full Text] [Related]

  • 6. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine.
    Nathan RS, Perel JM, Pollock BG, Kupfer DJ.
    J Clin Psychiatry; 1990 Sep; 51(9):367-72. PubMed ID: 2120201
    [Abstract] [Full Text] [Related]

  • 7. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
    Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM.
    J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993
    [Abstract] [Full Text] [Related]

  • 8. Fluvoxamine in the treatment of tricyclic-resistant depression.
    White K, Wykoff W, Tynes LL, Schneider L, Zemansky M.
    Psychiatr J Univ Ott; 1990 Sep; 15(3):156-8. PubMed ID: 2123039
    [Abstract] [Full Text] [Related]

  • 9. A Belgian multicentre study of fluvoxamine in depressive outpatients.
    Brasseur R, Van Moffaert M, Mesotten F, Ansseau M, Uytdenhoef P, Bartholome F.
    Acta Psychiatr Belg; 1985 Sep; 85(5):636-43. PubMed ID: 3937441
    [Abstract] [Full Text] [Related]

  • 10. Maprotiline versus imipramine and placebo in neurotic depression.
    van der Velde CD.
    J Clin Psychiatry; 1981 Apr; 42(4):138-41. PubMed ID: 7009592
    [Abstract] [Full Text] [Related]

  • 11. CGP 12.103 A versus clomipramine in the treatment of depressed inpatients--results of a double-blind study.
    Wolfersdorf M, Wendt G, Binz U, Steiner B, Hole G.
    Pharmacopsychiatry; 1988 Jul; 21(4):203-7. PubMed ID: 3060885
    [Abstract] [Full Text] [Related]

  • 12. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression.
    March JS, Kobak KA, Jefferson JW, Mazza J, Greist JH.
    J Clin Psychiatry; 1990 May; 51(5):200-2. PubMed ID: 2110560
    [Abstract] [Full Text] [Related]

  • 13. Double-blind study of oxaprotiline versus clomipramine in the treatment of depressive inpatients.
    Wolfersdorf M, Binz U, Wendt G, Metzger R, Hole G.
    Neuropsychobiology; 1987 May; 17(1-2):41-8. PubMed ID: 3306439
    [Abstract] [Full Text] [Related]

  • 14. Dexamethasone suppression test as an aid for selection of specific antidepressant drugs in patients with endogenous depression.
    Rihmer Z, Arató M, György S, Révai K, Demeter E.
    Pharmacopsychiatry; 1985 Sep; 18(5):306-8. PubMed ID: 4048265
    [Abstract] [Full Text] [Related]

  • 15. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR.
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [Abstract] [Full Text] [Related]

  • 16. Flupenthixol and fluvoxamine in mild to moderate depression: a comparison in general practice.
    Hamilton BA, Jones PG, Hoda AN, Keane PM, Majid I, Zaidi SI.
    Pharmatherapeutica; 1989 Jun; 5(5):292-7. PubMed ID: 2501801
    [Abstract] [Full Text] [Related]

  • 17. Predicting therapeutic results with levoprotiline and maprotiline in major depression: the role of the outcome criteria.
    Filip V, Höschl C, Karen P, Seifertová D, Bornová L, Prasková H, Prasko J.
    Br J Psychiatry Suppl; 1993 Sep; (21):35-8. PubMed ID: 8217066
    [Abstract] [Full Text] [Related]

  • 18. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K.
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [Abstract] [Full Text] [Related]

  • 19. [Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].
    Classen W.
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():41-3. PubMed ID: 2587675
    [Abstract] [Full Text] [Related]

  • 20. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline.
    Den Boer JA, Westenberg HG.
    Int Clin Psychopharmacol; 1988 Jan; 3(1):59-74. PubMed ID: 2833543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.